Guinea-Bissau Halts Controversial US-Backed Newborn Vaccine Trial 2026

Guinea-Bissau has halted a controversial US-backed hepatitis B vaccine trial in African newborns, the lead researcher confirmed, following global backlash and government denial of approval. The study, which was to be funded by the US Centers for Disease Control and Prevention (CDC) and private partners, will not proceed in the West African nation.

Why Was the Vaccine Trial Halted?

The trial was stopped because the researchers did not receive the necessary governmental approval, according to Frederik Schaltz-Buchholzer, a Danish researcher who led the project. In a LinkedIn post on Wednesday, he wrote that it is “now clear” that the study “will not move forward in Guinea-Bissau.”

This follows statements from Guinea-Bissau’s health minister, Quinhin Nantote, who last week denied that the project would move forward. “This is not even remotely true,” Nantote told the Guardian in Portuguese, referring to claims that the trial had been approved.

What Was the Proposed Study?

The study aimed to test the hepatitis B vaccine in newborns, with funding of $1.6 million from the CDC and an additional $1.6 million from private partners including the Bill Ackman-backed Pershing Square Foundation and the Bluebell Foundation. The total budget was $3.2 million.

The trial drew criticism from vaccine experts, including Paul Offit of the Children’s Hospital of Philadelphia, who called the proposed study unethical. Offit argued that the solution should be to “take the money and vaccinate as many kids as you can” rather than conduct a trial that withheld the vaccine from some infants.

Conflict Over Approval and Vaccine Possession

The situation escalated when Guinea-Bissau authorities searched the offices of the Bandim Health Project on Monday and apprehended the researchers’ vaccines. The government now has control over the vaccines, which were intended for the trial.

This action underscores the tension between the researchers and the Guinean government, which had not granted approval for the study. The government’s stance was clear from the start, with the health minister publicly refuting any suggestion that the trial was authorized.

What This Means for Vaccine Research and Public Health

The halt of this trial highlights the importance of ethical oversight and government approval in medical research, especially in vulnerable populations such as newborns. It also raises questions about how international research collaborations are conducted and funded.

Offit emphasized that it is vital to support Guinea-Bissau in rolling out immunizations to all newborns as soon as possible. Currently, Guinea-Bissau plans to offer the universal birth dose of the hepatitis B vaccine in 2028. The background to this story is set out in RFK Jr's Praised Vaccine Researchers Face Police Raid in Guinea-Bissau. A related thread runs through Guinea-Bissau New Constitution Expands Presidential Powers.

The controversy has also drawn attention to the role of private funders in global health research. The involvement of foundations backed by wealthy individuals can bring much-needed resources, but it also invites scrutiny over priorities and influence. Earlier coverage in Mpox in Guinea-Bissau: Children at Risk as Epidemic Spreads shows how the argument developed. A closer look at the same subject appears in Business: latest articles.

Key Takeaways

• The hepatitis B vaccine trial in Guinea-Bissau was halted due to lack of government approval.
• The study was funded by the CDC and private partners, including the Pershing Square Foundation and Bluebell Foundation.
• Vaccine expert Paul Offit criticized the study as unethical and called for immediate vaccination of newborns.
• Guinea-Bissau authorities seized the researchers’ vaccines and now control them.
• The government plans to introduce the universal birth dose in 2028.

Comparison of Trial Elements

The halted trial serves as a reminder of the complexities involved in global health research. For those following similar controversies, the Guinea-Bissau denies approval of controversial newborn vaccine trial provides essential background on the government’s position. Understanding the initial green light claims is also crucial, as detailed in our report on how the controversial vaccine trial in Guinea-Bissau gets green light was portrayed.

These developments underscore the need for transparent communication and ethical rigor in vaccine research. As the global health community watches, the focus must remain on protecting the health of newborns and ensuring that research is conducted with proper oversight.